Shi et al.’s work found that lncRNA-NEF plays a key role in mediating oxaliplatin chemotherapy resistance in CRC, providing a promising therapeutic strategy for CRC patients resistant to oxaliplatin (169). Here, S100B is linked to colorectal carcinoma.